A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension

Table 3 Change in IOP (mmHg) from baseline to week 4 (worse eye, ANCOVA, ITT population using LOCF)

Latanoprost concentration (μg/mL)
	50	75	100	125
N	71	70	72	69
8 a.m. IOP
LS mean change (mmHg)*	−9.72	−9.49	−10.04	−9.23
Adjusted difference in LS mean ± SEM^†		0.23 ± 0.58	−0.32 ± 0.58	0.49 ± 0.58
(90% CI)		(−0.72, 1.19)	(−1.27, 0.63)	(−0.47, 1.45)
p-value^‡		0.657	0.289	0.802
4 p.m. IOP
LS mean change (mmHg)*	−8.47	−7.96	−8.84	−8.49
Adjusted difference in LS mean ± SEM^†		0.51 ± 0.63	−0.36 ± 0.62	−0.02 ± 0.63
(90% CI)		(−0.53, 1.55)	(−1.39, 0.67)	(−1.06, 1.02)
p-value^‡		0.792	0.280	0.488

ANCOVA analysis of covariance, CI confidence interval, IOP intraocular pressure, LS least square, ITT intent to treat, SEM standard error of the mean.
*Adjusting for baseline IOP (covariate) with dose group and center as factors.
^†Higher concentration minus latanoprost 50 μg/mL; a negative difference in LS mean indicates that the higher concentration has a greater effect than latanoprost 50 μg/mL.
^‡One-sided p-value.

ISSN: 1471-2415